Objective: Medication noncompliance is a significant problem for effective pharmacologic treatment of major depressive disorder (MDD). Attempts to explore predictors of compliance have primarily focused on demographic characteristics; for the most part, these have been shown to be unrelated to compliance. Conversely, the relation between personality characteristics and compliance has been relatively understudied. The primary purpose of this study was to explore the relation between personality characteristics and compliance with antidepressant medication in patients with major depressive disorder (MDD).
M ajor depressive disorder (MDD), defined by the presence of one or more major depressive episodes (MDEs), is a common psychiatric condition with a point prevalence of approximately 4% among adults (1) and a lifetime risk for men and women of 12% and 20%, respectively (2, 3) . MDD is often a chronic disorder: up to 40% of patients continue to meet diagnostic criteria 1 year after symptom onset (4, 5) . MDD is also a serious condition associated with considerable comorbidity, disability, morbidity, and mortality (6, 7) . Despite increasing therapeutic choice among antidepressant agents available to treat MDD, medication compliance is often a major obstacle in both acute and long-term treatment of the disorder (8) .
The definition of compliance varies depending on the context in which it is being discussed. As well, compliance can have different meanings to clinicians and patients. In the medical context, for example, clinicians refer to compliance as the degree to which patients adhere behaviourally to their prescribed treatment regimen (most commonly, medications) (9, 10) . To suggest a more interactive, collaborative, and proactive approach, some researchers and clinicians have suggested using the terms adherence or alliance, rather than compliance (9) (10) (11) (12) . At present, the terms adherence and compliance are used interchangeably (for example, 13, 14) . Further, Besch states that, although compliance may be encouraged, it is still voluntary and within the individual's control (13) . It is apparent that the term compliance, despite its limitations, continues to be widely used in the medical and psychiatric literature (10, 15, 16) . Therefore, we use the term compliance in this paper.
Noncompliance with prescribed antidepressant medication regimens remains an important barrier to the effective pharmacologic treatment of MDD (14, (17) (18) (19) (20) . Mounting evidence indicates that increased compliance is a factor in reducing future depressive episodes and preventing patterns of relapse and recurrence (21) (22) (23) . Conversely, noncompliance has been found to be positively associated with poor treatment response (12) and risk of recurrence (21) and to be negatively associated with quality of life (5) . All these factors contribute to the enormous economic costs associated with mood disorders, estimated to be in the order of $30.4 billion annually in the US (24) .
Clinically significant noncompliance to antidepressants has been observed during the acute, continuation, and maintenance phases of treatment (14, 17) . Up to 60% of patients do not comply with their prescribed antidepressant regimen (17, 25, 26) . Lin and colleagues reported that approximately 28% of patients stopped taking their antidepressants during the first month of therapy and as many as 44% had stopped taking their antidepressants by the third month (14) .
Noncompliance with antidepressant regimens can affect both the efficacy of the drugs and their side effect profiles (27) . An effective antidepressant may be deemed ineffective if taken irregularly, resulting in unnecessary dosage increases (28) (29) (30) or inappropriate switching to another medication (31) . Indeed, treatment noncompliance is said to be one of the most prominent preventable causes of failure to respond to treatment (32) .
Treatment noncompliance, while widely documented, remains one of the least understood health-related behaviours. Its determinants are multifaceted and complex (9, (14) (15) (16) 18, 33) . Knowledge of patient characteristics that predict potential medication noncompliance can contribute to the formulation of a strategy for individualized treatment plans. Noncompliance may be minimized by identifying patients who are most at risk and developing appropriate interventions to address the risk factors. In searching for determinants of noncompliance with prescribed medication, investigators have primarily examined 2 broad categories: first, clinical factors (for example, patient-, illness-, drug-, and physician-related factors, as well as social influences and normative beliefs); and second, attitudes and beliefs regarding illness and treatment (19) .
Very little empirical research has been conducted on the relation between personality and compliance with antidepressant medication. Sirey and colleagues (34) used the Inventory of Interpersonal Problems (IIP) (35) to screen for personality pathology and reported that antidepressant compliance was associated with the absence of personality pathology. However, it is not clear whether the IIP measures personality pathology. Ekselius and others (36) used the Karolinska Scales of Personality (37) to investigate the relation between personality traits and compliance with antidepressant medication. These researchers found that medication noncompliance-determined based on out-of-range plasma levels of medication-was associated with elevated scores on the Sensation-Seeking subscale. Similarly, Wingerson and others (38) found that, in patients with panic disorder and generalized anxiety disorder, early discontinuation from clinical trials was positively associated with the "novelty seeking" dimension on the Tridimensional Personality Questionnaire (39) . Some other anecdotal literature does suggest an association between personality factors and medication noncompliance in psychiatric populations (9, 12, 40) . Based on evidence from the combined use of the Minnesota Multiphasic Personality Inventory (MMPI-2) Basic and Content Scales for depression and the NEO Personality Inventory (NEO PI), Stein and Hackerman hypothesized that the following indicate potentially poor treatment compliance: low MMPI-2 Content scores on the subscales Work Interference and Negative Indicators and low NEO PI scores on the dimension Conscientiousness coupled with high scores on the dimension Neuroticism (40) . However, these conclusions were drawn from a single case study, and a prospective controlled approach is required to confirm or refute them.
Our study was designed as a prospective investigation of the relation between personality, as measured by the NEO PI-Revised Version (NEO PI-R) (41) , and compliance with antidepressant medication in a population of patients receiving treatment for an episode of major depression in the context of MDD.
Method

Subjects
Participants were outpatients treated at the Depression Clinic, Centre for Addiction and Mental Health, University of Toronto, Toronto, Ontario, who met the following inclusion criteria: presence of an MDE; not suffering from psychosis (currently or in the past 12 months); receiving or about to start antidepressant therapy; and able and willing to provide meaningful, written, informed consent. Exclusion criteria included substance abuse or dependence currently or in the past 6 months; bipolar or psychotic disorders; or a clinically significant unstable medical condition (including but not limited to neurologic, cardiovascular, renal, and gastrointestinal disease), as determined by the treating psychiatrist. Most patients who attend this tertiary care clinic have recurrent and often chronic MDD.
Measures
To assess depression severity, we used the 17-item Hamilton Rating Scale for Depression (HRSD) (42) in the semistructured interview format (43) . We used the NEO PI-R (41) to measure 5 dimensions of personality: Neuroticism, Extraversion, Openness-to-Experience, Agreeableness, and Conscientiousness. Neuroticism is the predisposition to experience psychological stress and is manifested by anxiety, anger, depression, or other negative affects. Extraversion includes sociability, liveliness, and cheerfulness. Opennessto-Experience comprises aesthetic sensitivity, intellectual curiosity, need for variety, and nondogmatic attitudes. Agreeableness consists of trust, altruism, and sympathy. Conscientiousness encompasses a disciplined striving after goals and a strict adherence to principles (41) .
We used the Toronto Side Effects Scale (TSES) (44) to measure the frequency and severity of the side effects most commonly associated with antidepressant medication. Frequency ratings ranged from "never" = 1 to "every day" = 5, and severity ratings ranged from "no trouble" = 1 to "extreme trouble" = 5. Higher scores indicate greater frequency and (or) severity of side effects.
We used the Medication Event Monitoring System (MEMS; APREX Corporation, Fremont, CA) to evaluate compliance. This electronic system provides data on time and frequency of opening and closing of the medication container. Openings and closings recurring within 15 minutes of one another were ignored, as they were assumed to indicate difficulties in either opening or reclosing the lid. This methodology assumes that opening the MEMS container correlates with medication compliance.
We defined compliance as the percentage of days on which we assumed that patients took the correct amount of their prescribed antidepressant medication. More specifically, we defined compliance as the percentage of days on which the number of container-opening events coincided with prescribing instructions. We calculated compliance rates for 3 time periods: for 0 to 2 weeks after enrollment, for 0 to 4 weeks after enrollment, and for the 14-week period of the study. Individual medication compliance rates were manually computed as percentages according to the following formulae: These formulae for calculating compliance do not distinguish between normal dosing and overdosing. Conversely, they do not incorrectly penalize opening the MEMS to add medication to the container or to count pills.
Procedure
All potential subjects received a standard psychiatric assessment from a staff psychiatrist at the Depression Clinic, Centre for Addiction and Mental Health, University of Toronto. We gave those who met entry criteria a brief outline of what participation in the study involved and informed them that their compliance with antidepressant medication would be monitored for the following 14 weeks. After we obtained written informed consent for research participation, a trained research coordinator administered the Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P) Version 2.0 (45), together with the HRSD. The self-report NEO PI and TSES were also completed. One author saw all subjects every 2 weeks to administer the HRSD and collect TSES and MEMS data.
Results
Sample Characteristics
Of the 71 patients who were asked to participate in this study, 6 declined. The remaining 65 outpatients included 38 women (58.5%) and 27 men (41.5%) with a mean age of age of 41.4 years (SD 11.4 years). Eight patients were excluded from further analyses, 2 for misuse of the MEMS (that is, for providing inaccurate data), 2 for treatment reasons, and 4 for failing to attend a minimum of 2 clinic visits. We therefore further analyzed 57 patients, and all subsequent reports are based on this sample. Owing to missing data, subsequent analyses show some variation in the number of subjects.
Of the 57 subjects, 34 were women (59.6%) and 23 were men (40.4%), aged 21.7 to 74.1 years (mean 41.2 years, SD 10.8).
The ages of the men (mean 42.9 years, SD 9.6) and women (mean 40.1 years, SD 11.6) did not differ significantly (t 55 = 0.963, P = 0.340). The sample was predominantly white. Eighteen patients (31.6%) were married or living with someone as if married; 22 (38.6%) had never been married; 3 (5.3%) were widowed; and 8 (14%) and 4 (7.0%) participants had been divorced or separated, respectively. Less than one-half (47.4%) were working, almost one-third (31.6%) were receiving disability payments, and 6 (10.5%) were students.
Axis I Diagnoses. At the time of enrolment, 46/57 subjects (80.7%) met criteria for current MDD (DSM-IV), and 11/57 subjects (19.3%) met criteria for MDD in partial remission. Those in partial remission had been diagnosed with MDD in the past 12 months. Of the 46 individuals who met criteria for current MDD, 17 (29.8%) had melancholic features, and 10 (17.5%) had atypical features. As well, 13 (22.8%) individuals met criteria for "double depression," or concurrent dysthymia and MDD. Of the total 57 subjects, 28 (49.1%) had at least 1 secondary Axis I disorder, predominantly across anxiety disorder diagnoses (see Table 1 ).
Medications. Of the 57 subjects, 18 (31.6%) were treated with a selective serotonin reuptake inhibitor. Of these 18 subjects, 4 (7%) were taking fluoxetine, 9 (15.8%) were taking paroxetine, 4 (7%) were taking sertraline, and 1 (1.8%) was taking citalopram. Twenty-six (45.6%) individuals were being treated with bupropion, 3 (5.3%) were taking moclobemide, 8 (14%) were prescribed venlafaxine, and 2 (3.5%) were taking nefazodone. Most subjects were in the midst of ongoing treatment when they entered this study, and these figures represent the medications that they were taking at the time of enrolment. In some cases, medications were switched owing to poor response or adverse events.
Approximately one-third of our subjects were receiving combined therapy: 14 (24.6%) were taking 2 antidepressants, and 3 (5.3%) were taking 3 antidepressants. In these cases, we monitored compliance with the primary antidepressant medication, as identified by the subject's treating psychiatrist. As well, approximately 50% of subjects were taking anxiolytic or hypnotic medication. Dosing regimens were limited to either once daily or twice daily.
Medication Compliance in the Short and Long Term
We found the mean compliance rate for the first 2 weeks to be 92.5% (SD 10.7%), while the mean compliance rate for the first 4 weeks was 89% (SD 13.6%). The distributions of both the 2-week and 4-week compliance data were skewed (-1.781 and -1.836, respectively), and the Kolmogorov-Smirnov Test revealed that both distributions differed significantly from a normal distribution (P = 0.000, P = 0.013, respectively). As a result, we performed a logit transformation on the compliance data. Because the data were in percentages, we used the following transformation: (log10 [{compliance rate + 0.5}/{101 -compliance rate}]). Also, because log 0 cannot be defined, we adjusted the formula to guard against individuals whose compliance was either 0% or 100%. A similar logit transformation did not successfully normalize the 2-week or 4-week compliance data, which still differed highly from normal data (P < 0.001, P = 0.032).
Mean compliance for the 14-week study period was 83.4% (SD 16.3). The distribution was negatively skewed (-1.658), and the Kolmogorov-Smirnov Test revealed that it differed significantly from a normal distribution (P = 0.021). As a result, we performed a logit transformation on the compliance data. This logit transformation successfully normalized the data, and the Kolmogorov-Smirnov Test revealed that the distribution did not differ significantly from normal (P = 0.805). While the change in mean compliance was negligible at 84.1%, the variability increased (SD 50.2). All subsequent analyses that incorporate compliance data are based on the 14-week log-transformed compliance scores.
We conducted a 1-way repeated measures analysis of variance (ANOVA) to investigate compliance rates over time.
When we used an epsilon-adjusted F-test, the ANOVA revealed a significant time effect (F 2,90 = 2596.972, P = 0.000). Post hoc analyses using Tukey's HSD procedure to test the pairwise difference between means at the familywise 0.05 level showed that compliance declined significantly from the 2-week to the 14-week period (HSD 90,3 = 6.010, P < 0.05). 
Relation Between Sociodemographic, Clinical, and Treatment Variables and Compliance
Severity of Depression and Compliance.
Using HRSD scores from the 7 study visits over time, we conducted a 1-way repeated measures ANOVA to investigate changes in depression severity. When we used an epsilon-adjusted F-test, the ANOVA revealed a nonsignificant time effect (F 5,65 = 0.389, P = 0.817). Owing to the small sample size resulting from missing data, we conducted a 1-way repeated measures ANOVA using HRSD data corresponding to the compliance data reported (that is, at baseline, week 2, week 4, and week 14). The ANOVA revealed a nonsignificant time effect (F 3,90 = 0.872, P = 0.459). Because HRSD scores did not vary significantly over time, we calculated a mean HRSD score (mean 14.5, SD 6.2). There was no significant relation between depression severity and compliance (r 55 = -0.146, P = 0.280).
We analyzed the relation between compliance and depression severity in a 2-step multiple regression analysis, with HRSD scores at baseline (mean 16.0, SD 7.1) entered as the first step and HRSD scores at week 14 (mean 13.3, SD 7.5) entered as the second step. Neither the HRSD baseline scores nor the HRSD week 14 scores accounted for a significant amount of the compliance variability (F 1,50 = 0.426, P = 0.517, 0 2 = 0.01; F 2,49 = 0.555, P = 0.578, 0 2 = 0.01, respectively).
Side Effects and Compliance. We conducted a 1-way repeated measures ANOVA to investigate the frequency and severity of side effects over time. Each mean score considers both the frequency and the severity of the side effects. The ANOVA results revealed a nonsignificant time effect (F 7,329 = 0.600, P = 0.756). Because TSES scores did not vary significantly over time, we calculated a mean score (mean 4.26, SD 1.87).
There was no significant relation between side effects and compliance (r 55 = 0.036, P = 0.789).
Personality Characteristics and Compliance. We compared mean scores on the 5 NEO dimensions with published means for a comparable depression patient population (46) and found them to be similar. We conducted a multiple regression analysis to predict medication compliance from the NEO dimensions. The predictor variables were the 5 dimensions of To investigate the relation between the various facets of each of the 5 NEO dimensions and medication compliance, we analyzed correlations. We found significant relations between compliance and the following facets: Activity (Extraversion dimension), r 47 = -0.365, P = 0.005; Feelings (Opennessto-Experience dimension), r 47 = -0.248, P = 0.043; and Modesty (Agreeableness dimension), r 47 = 0.372, P = 0.004.
To investigate whether these facets significantly predicted medication compliance, we conducted bivariate linear regression analyses with the facets as the independent variable and medication compliance as the dependent variable. We found that Activity is a significant negative predictor of compliance to antidepressant medication ( 
Discussion
This study's primary goal was to investigate the relation between medication compliance and personality characteristics in individuals with MDD. The findings with respect to personality dimensions and medication compliance are intriguing and potentially important. It is known that personality pathology is a significant negative predictor of outcome (47, 48) ; however, past research dealing with the relation between personality and compliance in depression patients is limited and speculative. This study found that Extraversion (and specifically, differences in the Activity facet within the Extraversion dimension) was negatively related to antidepressant compliance and significantly predicted medication noncompliance. Characteristics of Extraversion include liking people, excitement, and stimulation, as well as being active. People with elevated Extraversion scores also tend to prefer large groups and gatherings and tend to be cheerful in their disposition toward others (41) . Individuals with a high Activity score tend to be energetic, quick, determined, enthusiastic, aggressive, and active (41) . Such people may be "too busy" or too engaged to remember or prioritize taking medication. Although Excitement Seeking as measured by the NEO PI-R was not significantly related to medication compliance, these findings are consistent with those of Ekselius and colleagues (36), who found that noncompliance with antidepressant medication was associated with a sensation-seeking personality. They are also in line with other reports that found a strong association between "novelty seeking personality traits" in patients with panic disorder and generalized anxiety disorder and early discontinuation from clinical trials, another form of noncompliance (38) .
Elevated scores on the Feelings facet of Opennessto-Experience were also significantly related to compliance: elevated scores were negatively associated with medication compliance. Characteristics of the Feelings facet include being excitable, spontaneous, insightful, imaginative, affectionate, talkative, and outgoing (41) . Taken together, the characteristics associated with Feelings, coupled with the characteristics associated with the facet Activity, particularly being energetic, hurried, quick, excitable, and spontaneous, are somewhat related to characteristics of ExcitementSeeking. It is speculated that high scorers on both Activity and Feelings are similar in certain ways to those with an Excitement-Seeking personality.
Another facet that was significantly related to, and a positive predictor of, medication compliance was Modesty (within the Agreeableness dimension). Interpreting this finding is not straightforward. Interestingly, and as for Extraversion, a considerable part of the Agreeableness scale is interpersonal in nature (41) . Individuals with a high score on this scale can be described as being humble and self-effacing. They may show more deference to authority and be more likely to follow medication instructions closely. Individuals with depression who are humble may also have more insight into their condition and therefore be more likely to follow their prescribed medication regimen. The "flip side" of modesty is narcissism.
Patients who have narcissistic tendencies as well as elevated scores for Extraversion, particularly on the Activity facet, are more likely not to comply with a prescribed medication regimen. Interestingly, the Compliance facet of the Agreeableness dimension was not associated with medication compliance in this study.
This study has several limitations that need to be considered. First, while the MEMS is said to be the current gold standard for measuring medication compliance, issues do exist regarding its reliability and validity. In particular, it is assumed that medication is ingested when the MEMS container is opened. Also, it could be argued that the compliance rate reported in this study is unusually high. Other studies have reported rates of noncompliance with antidepressants around 60% (14, 17, 18, 25) . Yet, studies that have used the MEMS as a compliance measure in populations with depression have shown compliance rates comparable to those found in the present study (49, 50) . However, frequent patient contact in this study may have produced artificially high compliance rates. Individuals were seen every 2 weeks and also received telephone calls to confirm appointments. This likely exceeded standard practice over a 3-month window of routine treatment. Demyttenaere and colleagues, for example, reported that clinic visits had a positive effect on compliance behaviour in the short-term (26) . It is also possible that the "Hawthorne effect" (whereby individuals modify their behaviour when they know they are being measured) indirectly increased compliance rates: not only was contact frequent, compliance was also closely monitored. However, Cramer and colleagues found that the "Hawthorne effect" dissipated after the first few days and that individuals returned to their normal behaviour patterns (49) . Nonetheless, we cannot exclude the possibility that many patients maintained an artificially high level of compliance throughout the study.
It has also been acknowledged that the nature and continuity of the doctor-patient relationship (including, for example, regular follow-up and empathy) is key to improving both medication compliance and treatment outcome (12, 16, 19) . This study provided excellent continuity of care, in the form of regular follow-up appointments, and involved the research team as well as the treating psychiatrist. We believe that a therapeutic alliance was developed with most, if not all, study participants. Thus, it is probable that the degree of compliance we observed was influenced by the nature of the patient-staff relationship.
As in previous reports (9,10,14,18), we did not find a significant relation between demographic variables and compliance with antidepressant medication. Severity of the depressive illness, both at baseline and at the end of the study, also did not significantly predict medication compliance. However, this finding may have been influenced by the relative lack of change in scores over the course of the study in a population with chronic depression. Others have also found a weak relation between severity of depression and compliance with antidepressant therapy (10, 14) , although Demyttenaere and colleagues found that a higher initial score on the HRSD predicted greater compliance (18) .
Side effects were not associated with medication compliance. This is consistent with research by Blackwell (51) and
Demyttenaere and colleagues (18) but contrasts with findings by Lin and colleagues, who found that severe levels of side effects were predictive of medication compliance levels (14) . Subjects in the present study were not considered noncompliant if they experienced severe side effects and were advised by their pharmacist or physician to discontinue or decrease the dosage of medication.
The inherent complications in compliance researchincluding how compliance is measured-contribute to its complexity. Nevertheless, the intricate relation between personality and medication compliance in patients with MDD requires further attention. Identifying predictors of compliance can help in the development of personalized treatment regimens and improve the clinical management of depression.
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Résumé : Le modèle de personnalité à 5 facteurs et l'observance des antidépresseurs
Objectif : La non-observance des médicaments est un problème important pour le traitement pharmacologique efficace du trouble dépressif majeur (TDM). Les tentatives de recherche sur les prédicteurs de l'observance ont principalement été axées sur les caractéristiques démographiques; celles-ci se sont révélées en grande partie non reliées à l 'observance. À l'inverse, la relation entre les caractéristiques de la personnalité et l'observance a été relativement sous-étudiée. Le principal objectif de cette étude était d 'explorer la relation entre les caractéristiques de la personnalité et l'observance des antidépresseurs chez les patients souffrant du trouble dépressif majeur (TDM).
Méthode : Sur une période de 14 semaines, nous avons évalué un échantillon de patients externes ( n = 65) qui recevaient un traitement aux antidépresseurs. Nous avons surveillé l'observance par électronique, à l'aide du système de surveillance des activités de médication (SSAM). Nous avons évalué les caractéristiques de la personnalité au moyen du NEO Five-Factor Inventory-Révisé. Nous avons aussi estimé la gravité de la dépression ainsi que la gravité et la fréquence des effets secondaires.
Résultats : L'extraversion était un prédicteur négatif significatif de l'observance, ce qui s'expliquait en grande partie par la relation entre l'observance et la facette activité de l'extraversion. Nous avons aussi constaté une relation négative entre la facette sentiments et l'observance, tandis que la facette modestie était un prédicteur positif significatif de l 'observance des antidépresseurs. La gravité de la dépression ou des effets secondaires ne prédisait pas l'observance.
Conclusions :
Ces résultats indiquent que les corrélations de la personnalité sont des prédicteurs importants, bien que souvent ignorés, de l'observance des antidépresseurs. Déterminer les prédicteurs de l'observance de la médication peut contribuer à l'élaboration de régimes de traitement individualisés et mener à de meilleurs résultats thérapeutiques dans le traitement du TDM.
